SCHEMBL673958

SCHEMBL673958

Brc1ccc2scc(CCc3ccccc3)c2c1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 5/20 0.59
CA2 P00918 1/20 0.49
MAPT P10636 3/20 0.44
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
UTS2R Q9UKP6 1/20 0.39
CCNC P24863 1/20 0.38
CDK8 P49336 1/20 0.38
DAO P14920 1/20 0.37
KEAP1 Q14145 1/20 0.37
NFE2L2 Q16236 1/20 0.37
PIM1 P11309 1/20 0.37
PIM3 Q86V86 1/20 0.37
PIM2 Q9P1W9 1/20 0.37
MTNR1A P48039 1/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31588788 0.80 CYP2A6 (0.67) CYP2A6CA2MAPTHDAC10HDAC11
SCHEMBL8547530 0.79 CYP2A6 (0.75) CYP2A6CA2MAPTHDAC10HDAC11
SCHEMBL6086462 0.78 MAPT (0.57) CYP2A6MAPTMTNR1ATP53
Hydrochloric Acid SCHEMBL23012014 0.78 CYP2A6 (0.73) CYP2A6CA2MAPTHDAC10HDAC11
SCHEMBL8253324 0.77 CYP2A6 (0.58) CYP2A6CA2MAPTHDAC10HDAC11
SCHEMBL4255979 0.76 CYP2A6 (0.71) CYP2A6CA2MAPTHDAC10HDAC11
SCHEMBL8653030 0.76 CYP2A6 (0.61) CYP2A6CA2MAPTHDAC10HDAC11
SCHEMBL8551337 0.75 CYP2A6 (0.59) CYP2A6CA2MAPTHDAC10HDAC11
SCHEMBL10667334 0.75 CYP2A6 (0.59) CYP2A6CA2HDAC10HDAC11HDAC8
SCHEMBL2217042 0.75 CYP2A6 (0.69) CYP2A6CA2MAPTHDAC10HDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8058245-B2 Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2011-11-15 US disclosed
US-20070197450-A1 Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof KISSEI PHARMACEUTICAL CO., LTD. 2007-08-23 US disclosed
EP-1721904-A1 FUSED HETEROCYCLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF Kissei Pharmaceutical Co., Ltd. (JP) 2006-11-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197450-A1 Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof SLC5A1, SLC5A2, GPR119 CYP2A6 346/4885CA2 2090/4885MAPT 3035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.